Avanos Medical (AVNS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual Meeting of Stockholders, originally set for April 21, 2026, has been postponed due to a pending merger announced on April 14, 2026.
Voting matters and shareholder proposals
No voting will occur as the annual meeting has been postponed in connection with the pending merger.
Shareholder rights and capital structure
Postponement of the annual meeting may impact the timing of shareholder votes and related governance actions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Avanos Medical
- Avanos to be acquired by AIP for $1.272B, going private with $25/share payout to shareholders.AVNS
Proxy filing14 Apr 2026 - Strategic growth, innovation, and M&A drive a $1B revenue vision by 2030.AVNS44th Annual J.P. Morgan Healthcare Conference13 Apr 2026
- Key votes include director elections, auditor ratification, and incentive plan amendment.AVNSProxy Filing12 Mar 2026
- Proxy covers director elections, pay, auditor ratification, and ESG progress, with all proposals supported.AVNSProxy Filing12 Mar 2026
- Focused on core growth, tariff mitigation, and innovation to drive strong financial performance.AVNSThe Citizens Life Sciences Conference 202611 Mar 2026
- FY25 net sales hit $701M; 2026 targets $700–$720M sales and $0.90–$1.10 EPS.AVNSQ4 202524 Feb 2026
- Q2 2024 saw strong sales, margin gains, and robust outlook led by Digestive Health.AVNSQ2 20242 Feb 2026
- Q3 2024 sales were $170.4M, Digestive Health grew, Pain Management fell, and leadership changed.AVNSQ3 202417 Jan 2026
- Enteral Feeding growth and cash flow strong, but impairment and HA pricing weigh on outlook.AVNSQ4 202423 Dec 2025